Pharmacological experiments show that this product can promote the phagocytosis of macrophages, improve the activity of NK cells and T lymphocytes in tumor-bearing mice, and the inhibition rate of W256 carcinosarcoma in rats, Lewis lung cancer and Sl80 sarcoma in mice, and human tumor QGY liver cancer is over 40%. The combination of cyclophosphamide and cyclophosphamide has a synergistic effect and has a certain protective effect on leukopenia in immunocompromised mice caused by cyclophosphamide.